Trial Profile
A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Desloratadine (Primary)
- Indications Allergic rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Organon
- 28 Apr 2014 New trial record